China Biopharmaceuticals (01177.HK) plans to acquire 95.09% stake in Lixin Pharmaceutical.
Finance and Economics APP News, China Biopharmaceuticals (01177.HK) announced that on July 15, 2025, the company's wholly-owned subsidiary, Sinopharm Investment (Beijing) Group Co., Ltd., intends to acquire 95.09% equity of Lixin Pharmaceuticals, for a consideration not exceeding approximately $951 million. Excluding Lixin Pharmaceutical Group's estimated cash and bank deposits of approximately $450 million on the delivery date, the net payment to be made by the buyer for the acquisition is approximately $501 million.
Latest
14 m ago